IM
ADCT icon

Islet Management’s ADC Therapeutics ADCT Stock Holding History

Islet Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-188,000
Closed -$6.2M – 114
2020
Q3 		$6.2M Buy
+188,000
New +$8.14M 0.43% 77

Other funds holding ADCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Islet Management's ADCT Position: Q4 2020 in Review

Islet Management sold out of ADC Therapeutics (ADCT) in Q4 2020, closing a stake of 188,000 shares — an estimated $6.2M sold.

Islet Management first reported a position in ADCT in Q3 2020 and held it in 1 quarter. The position peaked at $6.2M in Q3 2020. 51 funds tracked by Wall St. Rank hold ADCT as of Q4 2020.

  • Islet Management reported no remaining ADC Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Islet Management sold 188,000 ADC Therapeutics shares in Q4 2020, an estimated $6.2M.
  • Islet Management first reported a position in ADC Therapeutics in Q3 2020 and held it in 1 quarter.
  • Islet Management's ADC Therapeutics position peaked at $6.2M in Q3 2020.
  • 51 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2020.

Based on Islet Management's 13F filing for Q4 2020, filed 16 Feb 2021.